Literature DB >> 34205363

Impact of Aldosterone on the Failing Myocardium: Insights from Mitochondria and Adrenergic Receptors Signaling and Function.

Mariona Guitart-Mampel1, Pedro Urquiza1, Jordana I Borges2, Anastasios Lymperopoulos2, Maria E Solesio1.   

Abstract

The mineralocorticoid aldosterone regulates electrolyte and blood volume homeostasis, but it also adversely modulates the structure and function of the chronically failing heart, through its elevated production in chronic human post-myocardial infarction (MI) heart failure (HF). By activating the mineralocorticoid receptor (MR), a ligand-regulated transcription factor, aldosterone promotes inflammation and fibrosis of the heart, while increasing oxidative stress, ultimately induding mitochondrial dysfunction in the failing myocardium. To reduce morbidity and mortality in advanced stage HF, MR antagonist drugs, such as spironolactone and eplerenone, are used. In addition to the MR, aldosterone can bind and stimulate other receptors, such as the plasma membrane-residing G protein-coupled estrogen receptor (GPER), further complicating it signaling properties in the myocardium. Given the salient role that adrenergic receptor (ARs)-particularly βARs-play in cardiac physiology and pathology, unsurprisingly, that part of the impact of aldosterone on the failing heart is mediated by its effects on the signaling and function of these receptors. Aldosterone can significantly precipitate the well-documented derangement of cardiac AR signaling and impairment of AR function, critically underlying chronic human HF. One of the main consequences of HF in mammalian models at the cellular level is the presence of mitochondrial dysfunction. As such, preventing mitochondrial dysfunction could be a valid pharmacological target in this condition. This review summarizes the current experimental evidence for this aldosterone/AR crosstalk in both the healthy and failing heart, and the impact of mitochondrial dysfunction in HF. Recent findings from signaling studies focusing on MR and AR crosstalk via non-conventional signaling of molecules that normally terminate the signaling of ARs in the heart, i.e., the G protein-coupled receptor-kinases (GRKs), are also highlighted.

Entities:  

Keywords:  G protein-coupled receptor (GPCR); adverse remodeling; aldosterone; heart failure; mineralocorticoid receptor; mitochondria; mitochondrial bioenergetics; mitochondrial dynamics; mitochondrial dysfunction; signaling crosstalk

Year:  2021        PMID: 34205363     DOI: 10.3390/cells10061552

Source DB:  PubMed          Journal:  Cells        ISSN: 2073-4409            Impact factor:   6.600


  5 in total

Review 1.  Adrenal G Protein-Coupled Receptors and the Failing Heart: A Long-distance, Yet Intimate Affair.

Authors:  Jordana I Borges; Krysten E Ferraino; Natalie Cora; Deepika Nagliya; Malka S Suster; Alexandra M Carbone; Anastasios Lymperopoulos
Journal:  J Cardiovasc Pharmacol       Date:  2022-09-01       Impact factor: 3.271

2.  Plasma Biomarker Profiling in Heart Failure Patients with Preserved Ejection Fraction before and after Spironolactone Treatment: Results from the Aldo-DHF Trial.

Authors:  Moritz Schnelle; Andreas Leha; Abass Eidizadeh; Katharina Fuhlrott; Tobias D Trippel; Djawid Hashemi; Karl Toischer; Rolf Wachter; Christoph Herrmann-Lingen; Gerd Hasenfuß; Burkert Pieske; Lutz Binder; Frank Edelmann
Journal:  Cells       Date:  2021-10-19       Impact factor: 6.600

Review 3.  Natriuretic Peptide-Based Novel Therapeutics: Long Journeys of Drug Developments Optimized for Disease States.

Authors:  Tomoko Ichiki; Atsushi Jinno; Yoshihisa Tsuji
Journal:  Biology (Basel)       Date:  2022-06-03

4.  Right Ventricle Remodeling in Chronic Thromboembolic Pulmonary Hypertension.

Authors:  Jixiang Liu; Peiran Yang; Han Tian; Kaiyuan Zhen; Colm McCabe; Lan Zhao; Zhenguo Zhai
Journal:  J Transl Int Med       Date:  2022-07-02

Review 5.  Role and Mechanism of the Renin-Angiotensin-Aldosterone System in the Onset and Development of Cardiorenal Syndrome.

Authors:  Kexin Ma; Weifang Gao; Huazhou Xu; Wenjie Liang; Guoping Ma
Journal:  J Renin Angiotensin Aldosterone Syst       Date:  2022-01-24       Impact factor: 1.636

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.